Cancer Research Annual Meeting 2010 Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 68, 7090, September 1, 2008. doi: 10.1158/0008-5472.CAN-08-0643
© 2008 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin-Manso, G.
Right arrow Articles by Roberts, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin-Manso, G.
Right arrow Articles by Roberts, D. D.

Immunology

Thrombospondin 1 Promotes Tumor Macrophage Recruitment and Enhances Tumor Cell Cytotoxicity of Differentiated U937 Cells

Gema Martin-Manso1, Susana Galli1, Lisa A. Ridnour2, Maria Tsokos1, David A. Wink2 and David D. Roberts1

1 Laboratory of Pathology and 2 Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: David D. Roberts, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 2A33, 10 Center Drive MSC 1500, Bethesda, MD 20892. Phone: 301-496-6264; Fax: 301-402-0043; E-mail: droberts{at}helix.nih.gov.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
 References
 
Inhibition of tumor growth by thrombospondin (TSP) 1 is generally attributed to its antiangiogenic activity, but effects on tumor immunity should also be considered. We show that overexpression of TSP1 in melanoma cells increases macrophage recruitment into xenograft tumors grown in nude or beige/nude mice. In vitro, TSP1 acutely induces expression of plasminogen activator inhibitor-1 (PAI-1) by monocytic cells, suggesting that TSP1-induced macrophage recruitment is at least partially mediated by PAI-1. Tumor-associated macrophages (TAM) can either promote or limit tumor progression. The percentage of M1-polarized macrophages expressing inducible nitric oxide synthase is increased in TSP1-expressing tumors. Furthermore, soluble TSP1 stimulates killing of breast carcinoma and melanoma cells by IFN-{gamma}–differentiated U937 cells in vitro via release of reactive oxygen species. TSP1 causes a significant increase in phorbol ester–mediated superoxide generation from differentiated monocytes by interaction with {alpha}6β1 integrin through its NH2-terminal region. The NH2-terminal domain of TSP2 also stimulates monocyte superoxide production. Extracellular calcium is required for the TSP1-induced macrophage respiratory burst. Thus, TSP1 may play an important role in antitumor immunity by enhancing recruitment and activation of M1 TAMs, which provides an additional selective pressure for loss of TSP1 and TSP2 expression during tumor progression. [Cancer Res 2008;68(17):7090–10]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
 References
 
Thrombospondin 1 (TSP1) is a secreted glycoprotein that is predominantly stored in platelets but also secreted at low levels by many cell types, including monocytes and macrophages. TSP1 is rapidly and transiently released in response to tissue injury and is elevated in several chronic diseases (1, 2). TSP1-null mice display acute and chronic inflammatory pulmonary infiltrates and an elevated number of circulating WBCs (3), suggesting an anti-inflammatory role. In contrast, TSP1 expression in ischemic injuries limits tissue survival and restoration of perfusion by blocking nitric oxide/cyclic guanosine 3',5'-monophosphate signaling (4). The diverse biological activities of TSP1 are mediated by its multiple functional domains that engage corresponding receptors expressed by a variety of cells. Differential expression or activation of cell surface receptors for TSP1, including integrins, CD36, CD47, low-density lipoprotein (LDL) receptor-related protein, proteoglycans, and sulfatides, may dictate the specific responses of each cell type to TSP1 (5).

TSP1 plays several roles in the physiologic functions of phagocytes. TSP1 mediates phagocytosis of neutrophils undergoing apoptosis (6). Macrophage recognition and phagocytosis of apoptotic fibroblasts requires fibroblast-derived TSP1 and CD36 (7). CD36-deficient patients have impaired oxidized LDL-induced nuclear factor-{kappa}B activation and subsequent cytokine expression (8). TSP1 modulates expression of interleukin (IL)-6 and IL-10 by monocytes (9) and activation of latent transforming growth factor β (TGFβ; ref. 3). TSP1 stimulates motility of human neutrophils (10, 11) and promotes chemotaxis and haptotaxis of human peripheral blood monocytes (12). In addition, TSP1 enhances cytokine-induced respiratory burst of human neutrophils (13) and enhances chemoattractant fMLP-mediated superoxide anion (O2–) generation by human neutrophils through its NH2-terminal domain (14, 15). However, the underlying mechanism for regulation of O2– generation has not been delineated. Here, we provide evidence that soluble TSP1 causes a significant increase in phorbol 12-myristate 13-acetate (PMA)–mediated O2– generation from IFN-{gamma}–differentiated human monocytes by interaction with {alpha}6β1 integrin through its NH2-terminal region and identify a requirement for extracellular calcium to mediate the macrophage respiratory burst.

Macrophages are an important effector cell of innate immunity against tumors. However, tumor-associated macrophages (TAM) can differentiate into either cytotoxic (M1) or tumor growth–promoting (M2) states. This differentiation depends on the tissue microenvironment (16). Macrophages are classically activated toward the M1 phenotype by IFN-{gamma} alone or in concert with microbial products. Alternative activation by stimulation with IL-4 or IL-13, IL-10, IL-21, TGFβ, immune complexes, and glucocorticoids drives macrophages toward the M2 phenotype (17). M2 macrophages are present in most established tumors and promote tumor progression (18).

TSP1 is often down-regulated during tumor progression and inhibits tumor growth when reexpressed (19). This activity is generally attributed to angiogenesis inhibition, but the above results suggest that effects on tumor immunity should also be considered. The current study shows an important role for TSP1 as a positive modulator of innate antitumor immunity by increasing M1 macrophage recruitment and stimulating reactive oxygen species (ROS)-mediated tumor cytotoxicity.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosure of Potential...
 References
 
Proteins and peptides. Human TSP1 was purified from the supernatant of thrombin-activated platelets obtained from the NIH Blood Bank (20). Recombinant human TSP1 was obtained from EMP Genetech. Recombinant proteins containing various domains of TSP1 and TSP2 were prepared as previously described and provided by Dr. Deane Mosher (University of Wisconsin, Madison, WI; refs. 21–23). The {alpha}6β1 integrin inhibitory peptide (LALERKDHSG) derived from TSP1 and the control peptide (LALARKDHSG) were prepared as described (24). Xanthine, xanthine oxidase, and superoxide dismutase (SOD) were obtained from Stratagene.

Reagents. Rat anti-mouse CD68 antibody (clone FA-11) was from AbD Serotec. Monoclonal neutralizing antibody (clone 9016) against human TGFβ1, recombinant human and mouse IFN-{gamma}, recombinant human TGFβ1, and recombinant human IL-4 were from R&D Systems. Rabbit polyclonal to plasminogen activator inhibitor-1 (PAI-1) and rabbit polyclonal to inducible nitric oxide synthase (iNOS) were from Abcam, Inc. Anti-actin (Ab-1) mouse monoclonal antibody and EGTA were from Calbiochem. The function-blocking rat anti-human {alpha}6 integrin monoclonal antibody (clone G0H3) was from Chemicon International, Inc. FITC-conjugated rat anti-human {alpha}6 monoclonal antibody (clone G0H3) and the isotype control were from BD Biosciences. Lipopolysaccharide (LPS) from Escherichia coli 0111:B4 and PMA were from Sigma-Aldrich. The inhibitor of iNOS, aminoguanidine, was from Sigma-Aldrich. The {alpha}4β1 integrin antagonist [4-((2-methylphenyl)aminocarbonyl)aminophenyl] acetyl-LDVP (25) was obtained from Bachem. The calcium indicator Fluo-4/AM, rabbit polyclonal anti-fluorescein/Oregon Green, and Pluronic F-127 were from Molecular Probes.

THBS1-transfected cells. MDA-MB-435 cells transfected with the THBS1 expression plasmid (clone TH26, 7.5-fold higher TSP1 expression than control) or the empty pCMVBamNeo vector (Neo) were described previously (26).

Cell culture and differentiation. Transfected MDA-MB-435 cells were cultured at 37°C, 5% CO2, in complete RPMI 1640 (Life Technologies) containing 10% fetal bovine serum (FBS; Biosource), 2 mmol/L glutamine, 100 units/mL penicillin, 100 µg/mL streptomycin, and 750 µg/mL geneticin (Life Technologies). The human monocytic line U937 (27), kindly provided by Dr. Mark Raffeld [National Cancer Institute (NCI), NIH, Bethesda, MD], was cultured at 37°C, 5% CO2, in RPMI 1640 supplemented with 2 mmol/L glutamine, 100 units/mL penicillin, 100 µg/mL streptomycin, and 10% endotoxin-tested FBS (Biosource). For differentiation with IFN-{gamma}, 2.0 x 105/mL U937 cells in complete growth medium containing 1 mmol/L sodium pyruvate, 0.1 mmol/L MEM with nonessential amino acids (Cellgro), and 100 units/mL recombinant human IFN-{gamma} were incubated for 3 d at 37°C. For differentiation with IL-4, 2.0 x 105/mL U937 cells in AIM-V + Albumax serum-free medium (Life Technologies) containing 10 ng/mL recombinant human IL-4 were incubated for 3 d at 37°C. MDA-MB-231, MDA-MB-435, and MCF-7 cells were cultured in RPMI 1640 containing 10% FBS, 2 mmol/L glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. Murine macrophage cell lines ANA-1 (28) and RAW264.7 were cultured in DMEM (Life Technologies) supplemented with 2 mmol/L glutamine, 100 units/mL penicillin, 100 µg/mL streptomycin, and 5% endotoxin-tested FBS. Human peripheral blood mononuclear cells (PBMC) were prepared by gradient centrifugation. In brief, fresh human buffy coat (NIH Blood Bank) was diluted 1:4 with sterile Dulbecco's PBS (Life Technologies). Human PBMCs were isolated by mixing 1.077 g/mL Lymphocyte Separation Medium (Cambrex) and the diluted human blood and centrifuged for 30 min at 900 x g, 18°C to 20°C. Human monocytes were isolated from PBMCs by adherence to plastic.

Tumorigenesis assay in nude mice. Groups of 10 female NIH-bg/nu mice, ~8 wk of age, were injected in the mammary fat pads with 8 x 105 Neo or TH26 cells. Primary tumor size was determined twice weekly by length x width x height measurement. The primary tumors were removed on week 11.

A total of 15 female NIH-nu/nu mice, 7 wk of age, were s.c. injected in the right hind leg with 5 x 106 MDA-MB-435 cells. Five animals were injected with Neo cells and 10 with TH26 cells. Primary tumor size was determined twice weekly, and tumor volume was calculated as (width)2 x length/2. Primary tumors were removed when the volume was 300 to 400 mm3 or at week 7. For histopathologic analysis, tumor tissues were fixed in buffered formalin, embedded in paraffin, sectioned (5 µm), and stained with H&E. Animal experiments were conducted in an accredited facility according to NIH guidelines under a protocol approved by the NCI Animal Care and Use Committee.

Immunohistochemical evaluation. Slides were deparaffinized in xylene (thrice for 10 min) and rehydrated in graded alcohol (100%, 95%, and 70%). Antigen retrieval was performed in a pressure cooker containing Target Retrieval Solution (pH 6.10; Dako Corp.) for 30 min (CD68 antibody) or 10 min (PAI-1 antibody) or 10 mmol/L citrate buffer (pH 6.0) for 10 min, followed by cooling at room temperature for 20 min (iNOS antibody), and then washed with PBS twice for 10 min. Endogenous peroxidase activity was quenched by 0.3% H2O2 in water. After washing the slides with Wash Buffer Solution (Dako), nonspecific binding was reduced using Protein Block Serum-Free (Dako) for 10 min. The slides were incubated with CD68 antibody (1:100, overnight at 4°C), PAI-1 antibody (1:250 dilution, 1 h at room temperature), and iNOS antibody (1:50, 1 h at room temperature). Slides were then incubated with streptavidin-biotin (Dako LSBA+ kit, horseradish peroxidase). 3,3'-Diaminobenzidine (Dako) was used as chromogen for 5 min, and hematoxylin was used for counterstaining. Negative control slides omitted the primary antibody. CD68 was located predominantly within the cells. Nuclei were negative. Cytoplasmic and extracellular staining in macrophages was considered positive for PAI-1. Cytoplasmic staining in macrophages was considered positive for iNOS. The intensity of the staining was evaluated using a Nikon Eclipse E1000 microscope equipped with a microcolor camera (RGB-MS-C). The acquisition software was IPLab-Scientific Image Processing 3.5.5.

Measurement of monocyte chemotactic protein-1, PAI-1, and IL-10. Monocyte chemotactic protein-1 (MCP-1), PAI-1, and IL-10 levels in differentiated U937 cell supernatants were measured with a multiplex ELISA array (Quansys Biosciences). All samples were run in replicate.

Western blotting. RAW264.7 cells were serum deprived for 48 h before addition of TGFβ1 or TSP1. After 2 to 4 h of incubation at 37°C, 5% CO2, in AIM-V + Albumax serum-free medium, cells were lysed at 4°C in 0.5% deoxycholic acid, 0.1% SDS, 50 mmol/L HEPES, 1% Triton X-100, 1% NP40, 150 mmol/L NaCl, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 2 µg/mL aprotinin, 2 µg/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride. Cell pellets were vortexed briefly and centrifuged at 14,000 rpm for 15 min. Cell lysates (15 µg protein) were boiled for 5 min in SDS sample buffer, electrophoretically separated on NuPAGE 10% Bis-Tris gels (Invitrogen) for 1.5 h at 150 V, and transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore) for 2 h at 100 V. Membranes were blocked in 5% bovine serum albumin (BSA)/0.1% Tween 20/PBS and incubated overnight with rabbit polyclonal to PAI-1 (2.5 µg/mL). Enhanced chemiluminescence (Upstate) was used for detection. Stripped membranes were reprobed with actin antibody to confirm protein loading levels.

Real-time quantitative reverse transcription-PCR analysis. Total RNA was extracted from Neo and TH26 tumors using Trizol (Invitrogen) according to the manufacturer's instructions. Total RNA was treated with recombinant DNase I (DNA-free kit, Applied Biosystems) and quantified using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). cDNA was synthesized from total RNA using iScript cDNA Synthesis kit (BioRad). Real-time PCR for mouse iNOS and arginase-1 expression profiling was performed on a 7500 Real-Time PCR instrument (Applied Biosystems) using Taqman oligonucleotide primers Mm00440485_m1 and Mm00475988_m1, respectively. Data were normalized against mouse hypoxanthine phosphoribosyltransferase 1 (HPRT1; Mm00446968_1). Relative iNOS and arginase-1 expression was calculated using the 2–{Delta}{Delta}CT method.

U937 and ANA-1 cell-mediated cytolysis. MDA-MB-231, MDA-MB-435, and MCF-7 target cells were seeded into 16-well plates in 150 µL of growth medium. Cell growth was dynamically monitored using RT-CES system (ACEA Biosciences) for 24 h. Differentiated U937 effector cells at an E:T ratio of 40:1 were added into wells containing target cells. ANA-1 cells were activated for 20 h at 37°C with 10 ng/mL of LPS and 100 units/mL of IFN-{gamma} in complete medium and also used at an E:T ratio of 40:1. After addition of effector cells, measurements were automatically collected by the analyzer every 10 min for up to 48 h.

Cytotoxicity assay. MDA-MB-231 cells (2 x 104 per well) were seeded into 96-well plates in 200 µL of growth medium in the presence or absence of soluble TSP1 for up to 72 h at 37°C. MDA-MB-231 cells (2,500 per well) were seeded into 96-well plates in 100 µL of RPMI 1640 containing 1.25% FBS, 2 mmol/L glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin in the presence or absence of xanthine/xanthine oxidase for 72 h at 37°C. Media were collected to assess lactate dehydrogenase (LDH) released due to cell death. LDH release was quantified using a colorimetric assay (Promega). All samples were run in triplicate.

Superoxide production. O2– levels in differentiated U937 and activated ANA-1 cell supernatants were quantified using the LumiMax Superoxide Anion Detection kit (Stratagene).

Flow cytometry analysis. Direct immunofluorescence was performed by incubating 1 x 106 cells with 50 µg/mL of FITC-conjugated rat anti-human {alpha}6 antibody (clone G0H3) or isotype control for 45 min at 4°C in HBSS containing 0.1% BSA and 0.1% sodium azide (Sigma-Aldrich). After staining, propidium iodide was added and the cells were analyzed on a FACScan flow cytometer (Becton Dickinson). The analysis software was FlowJo (7.2.1).

Measurement of intracellular free Ca2+. Differentiated U937 cells were incubated with loading solution consisting of HEPES-buffered saline [11.6 mmol/L HEPES (Cellgro) in HBSS] supplemented with 2 µmol/L Fluo-4, 0.02% Pluronic F-127, and 1% BSA for 30 min and then incubated in loading solution without Fluo-4 for 30 min to allow deesterification of the probe. Loading solution was replaced with HBSS containing anti-fluorescein antibody and TSP1. The cells were then placed in a fluorometer (GENios Plus Tecan), and measurements were collected every 5 min for up to 40 min.

Statistical analysis. All data are shown as mean ± SD except were indicated. Significance was determined with one-tailed distribution Student's t test analysis. The difference was considered significant when P ≤ 0.05 (*) and P ≤ 0.001 (**).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosure of Potential...
 References
 
TSP1 overexpression increases tumor macrophage recruitment in vivo. Expression of TSP1 in the melanoma cell line MDA-MB-435 significantly inhibits tumor growth and metastasis (26). Notably, increased infiltration of monocytes was observed in clone TH26 tumors that highly express TSP1 (26) and in tumor-bearing mice treated with TSP1 peptides (29). Because macrophage recruitment into wounds is TSP1 dependent (1), we examined the effect of tumor cell TSP1 over expression on TAM recruitment. Using the previously described conditions of injection in the mammary fat pads (26), we confirmed that TH26 tumors showed delayed growth in female NIH-bg/nu mice relative to control-transfected clones (data not shown). The primary tumors were removed on week 11, and seven randomly selected mice were analyzed by immunohistochemistry. TAMs were detectable in nonnecrotic areas of tumor stained with H&E (data not shown). Based on CD68 antibody staining, the percentage of TAMs was significantly higher in TH26 tumors than in Neo tumors (P < 0.05; Fig. 1A ).


Figure 1
View larger version (49K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. THBS1 overexpression promotes macrophage recruitment in tumor-bearing nude mice. A, tissue sections cut from paraffin-embedded tumors harvested from NIH-bg/nu mice injected in the mammary fat pads with TH26 or Neo MDA-MB-435 clones were stained with H&E and rat anti-mouse CD68 antibody (clone FA-11). Quantitative analysis of macrophage infiltration into the tumor specimens was performed by evaluating the number of CD68-positive cells per 100x field in nonnecrotic areas. The results are presented as a percentage of TAMs in Neo control (white column) versus THBS1-transfected TH26 tumors (red column). B, primary tumor size 24 d after injection in NIH-nu/nu mice given s.c. injections of TH26 (red column) or Neo cells (white column). Histogram represents the tumor volume (mm3) of all animals within each group that developed a tumor. C, paraffin-embedded sections cut from clone TH26 tumors grown s.c. in NIH-nu/nu mice were stained with H&E (top) and rat anti-mouse CD68 antibody (clone FA-11; bottom). Representative photomicrographs of adjacent slides are shown from experiments conducted in tumor samples from 12 NIH-nu/nu mice. Three mice did not develop tumors. Identical patterns were observed in all of the tumors examined. Magnification, x200. D, quantitative analysis of macrophage infiltration into s.c. tumors grown in NIH-nu/nu mice was evaluated as the percentage of CD68-positive cells in multiple 100x fields in nonnecrotic areas. The results are presented as a percentage of TAMs in Neo (white column) and TH26 tumors (red column).

 
Mammary fat pad injection was used previously as an orthotopic model of breast carcinoma growth, but recent studies have confirmed that the MDA-MB-435 cell line is a derivative of the M14 melanoma cell line (30). To determine whether TSP1 suppresses tumor growth at a site more appropriate for melanoma, 15 female NIH-nu/nu mice were s.c. injected in the right hind limb with TH26 or Neo cells. TSP1 overexpression in TH26 cells also inhibited s.c. tumor growth (P ≤ 0.001; Fig. 1B). The primary tumors were removed when the volume was 300 to 400 mm3 or at week 7 and analyzed by immunohistochemistry. Sections of tumor were stained with H&E and anti-mouse CD68 antibody. Increased TAM infiltration was observed in s.c. TH26 versus Neo tumors (P < 0.001; Fig. 1C and D).

Role of MCP-1 and PAI-1 in TSP1-dependent TAM recruitment. MCP-1 is an important regulator of monocyte recruitment (31), and a deficit in MCP-1 was proposed to account for decreased infiltration of macrophages into an excisional wound of TSP1-null mice (1). However, 12 h of stimulation with different doses of soluble TSP1 resulted in no significant change in total MCP-1 release from differentiated U937 human monocytic cells (Fig. 2A, left ).


Figure 2
View larger version (53K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Effects of TSP1 on MCP-1 and PAI-1 expression in differentiated U937 human monocytic cells and mouse macrophages. A to C, differentiated U937 cells (1 x 106/0.5 mL RPMI 1640 with 0.5% FBS) were incubated in the presence or absence of soluble TSP1, soluble recombinant type 1 repeats of TSP1 (3TSR; B), or soluble recombinant human TSP1 (C, right). After 12 h of incubation (A), or at the indicated times (B and C, right), the supernatants were harvested, and total MCP-1 and PAI-1 were determined using a multiplex ELISA array as described in Materials and Methods. Data are representative of at least four different experiments. C, left, differentiated U937 cells were incubated with neutralizing TGFβ1 antibody (clone 9016) for 15 min before the addition of soluble TSP1 (20 µg/mL). Culture supernatants collected after 12 h were used to measure total PAI-1. Data are representative of two different experiments. D, left, serum-deprived murine RAW264.7 cells were stimulated with TGFβ1 (1 ng/mL), as a positive control, or soluble TSP1 (20 µg/mL) for 2 h. The experiment was repeated thrice, and a representative anti–PAI-1 blot is shown. Actin was used to confirm equal protein loading. Right, paraffin-embedded sections cut from TH26 tumors grown s.c. in NIH-nu/nu mice were stained with rat anti-mouse CD68 antibody (clone FA-11; left) and rabbit anti-mouse PAI-1 antibody (right). Representative photomicrographs of adjacent sections are shown from experiments conducted in tumor samples from 12 NIH-nu/nu mice. Identical patterns were observed in all of the tumors examined. Magnification, x200.

 
Macrophage migration in vitro and in vivo also depends on PAI-1 (32, 33), and elevated PAI-1 expression was previously reported in TH26 versus Neo cells (34). Therefore, increased PAI-1 could also account for increased TAM recruitment into TH26 tumors. Because this result was obtained using a stable transfectant, it was unclear whether TSP1 directly regulates PAI-1 expression rather than the increased PAI-1 being an indirect adaptation of the transfected clones. Incubation of differentiated U937 cells with TSP1 resulted in an acute dose- and time-dependent increase in PAI-1 expression, with a maximal 50-fold induction at 8 h [P < 0.001; Fig. 2A (right) and B]. Because PAI-1 is a TGFβ-inducible gene (35) and bioactive TGFβ is present in TSP1 purified from platelets (36), we asked whether TGFβ contamination or TSP1-mediated activation of latent TGFβ (3) contributed to the PAI-1 response in U937 cells. Interestingly, stimulation with 3 µg/mL of soluble recombinant 3TSR, the type 1 repeat domain of TSP1 responsible for the TSP1-mediated activation of latent TGFβ (37), resulted in no significant change in total PAI-1 release from differentiated U937 cells (Fig. 2B). Therefore, activation of latent TGFβ probably does not account for the effect of TSP1 on PAI-1 expression. The NH2-terminal module of TSP1 increases fMLP-mediated O2– generation and chemotaxis by human neutrophils (10, 14) but also had no effect in PAI-1 expression (data not shown).

TSP1 stimulation of PAI-1 production was then examined in the presence of a neutralizing TGFβ1 antibody. At 5 µg/mL, the neutralizing antibody partially inhibited TSP1-stimulated PAI-1 production (Fig. 2C, left). Furthermore, recombinant human TSP1 at the same concentration, which should lack TGFβ contamination, showed less stimulatory activity than platelet TSP1 (Fig. 2C, right). Therefore, bioactive TGFβ present in platelet TSP1 at least partially mediates the stimulation of PAI-1 production by TSP1, but TSP1 lacking TGFβ is also active.

To address whether TSP1 also induces PAI-1 production in mouse macrophages, we used the RAW264.7 macrophage cell line. Increased PAI-1 expression was detected in whole-cell lysates within 2 h after TGFβ (positive control) or TSP1 treatment (Fig. 2D, left). Furthermore, increased PAI-1 secretion was detected in cell culture supernatants within 4 h after TGFβ or TSP1 treatment (data not shown). We also examined whether PAI-1 is expressed by murine TAMs in vivo. Immunohistochemical analysis showed strong PAI-1 staining in the TH26 TAMs (Fig. 2D, right).

Increased M1 macrophage recruitment into TSP1-overexpressing tumors. Activated murine macrophages metabolize L-arginine via two main pathways that are catalyzed by the inducible enzymes iNOS and arginase. Increased iNOS is characteristic of M1 macrophages, and arginase-1 is a marker of M2 macrophages (38). To compare iNOS expression in vivo, total RNA extracted from six randomly selected Neo and TH26 tumors was analyzed using real-time PCR. A 3.8-fold increase in iNOS expression was found in TH26 tumors (Fig. 3A ). In contrast, the M2 marker arginase-1 was equally expressed in both tumors (data not shown). Staining of tumor sections using an iNOS antibody showed an increased percentage of iNOS-expressing TAMs in TH26 versus Neo tumors (P ≤ 0.001; Fig. 3B and C). Taken together, these data show that M1 cytotoxic macrophages are a minor fraction of the TAMs in MDA-MB-435 tumors, but their recruitment or differentiation is increased when the tumors express TSP1.


Figure 3
View larger version (48K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Increased iNOS-expressing M1 TAMs in TSP1-overexpressing tumors. A, real-time quantitative reverse transcription-PCR analysis of mRNA expression in TH26 and Neo tumors from six NIH-nu/nu mice. Fold difference was adjusted to HPRT1 internal control values. Relative quantification of iNOS was calculated by the 2–{Delta}{Delta}CT method. B, immunohistochemical analysis of TH26 and Neo tumors in NIH-nu/nu mice. Adjacent sections were stained using rat anti-mouse CD68 antibody (clone FA-11; top) and rabbit polyclonal antibody to iNOS to detect M1-differentiated TAMs (bottom). The results are representative of tumor samples from 12 NIH-nu/nu mice, which showed identical patterns. Magnification, x400. C, quantitative analysis of CD68-positive cells expressing iNOS in the tumor specimens was performed by evaluating the percentage of iNOS-positive macrophages in multiple 100x fields. The results are presented as the percentage of iNOS-positive TAMs in Neo control (white column) and TH26 tumors (red column). D, left, U937 cells (2 x 105/0.5 mL AIM-V) were incubated with IL-4 to induce M2 differentiation in the presence or absence of soluble TSP1. At the indicated times, the supernatants were harvested, and IL-10 was determined using a multiplex ELISA array as described in Materials and Methods. Right, U937 cells were differentiated with IL-4 for 72 h, and then the differentiated cells (1 x 106/1 mL AIM-V) were incubated with soluble TSP1. After 12 h of incubation, the supernatants were harvested, and IL-10 was determined using a multiplex ELISA array.

 
To address whether M2 macrophage differentiation or function is sensitive to TSP1 in vitro, U937 cells were differentiated using IL-4 for 72 h in the presence or absence of soluble TSP1. IL-10 levels in the cell culture supernatants, a marker of M2 polarization, showed no significant differences (Fig. 3D, left). Similarly, incubation of IL-4–differentiated U937 cells with soluble TSP1 (20 µg/mL) for 12 h did not alter IL-10 secretion (Fig. 3D, right).

TSP1 stimulates macrophage cytotoxicity toward breast carcinoma and melanoma cells. To determine whether TSP1 can regulate tumor cell killing by macrophages, we performed dynamic monitoring of macrophage-mediated cytolysis. IFN-{gamma}–differentiated U937 cells were incubated with MDA-MB-231 breast carcinoma cells (at an E:T ratio of 40:1) in the RT-CES system. The cell index readout assesses changes in viable adherent cells by electrical impedance. Differentiated U937 cells expressed constitutive cytotoxic activity against MDA-MB-231 cells (Fig. 4A ). Moreover, tumoricidal activity was increased 5-fold after 18 h of incubation with soluble TSP1 (5 µg/mL; Fig. 4A, left). This concentration of TSP1 did not show any direct cytotoxic activity against MDA-MB-231 cells (Fig. 4A, right). TSP1 similarly enhanced cytotoxicity against MDA-MB-435 melanoma and MCF-7 breast carcinoma cell targets (Fig. 4B, left and right, respectively). Because our in vivo model used a human tumor xenograft in mice, we also examined the mouse macrophage cell line ANA-1 as effector against human MDA-MB-231 target cells. Activated ANA-1 cells expressed constitutive cytotoxic activity against MDA-MB-231 cells in the presence of an iNOS inhibitor (0.5 mmol/L aminoguanidine) to permit O2– accumulation (39). A 10-fold increase in tumoricidal activity was recorded after 12 h of incubation with soluble TSP1 (5 µg/mL; Fig. 4C).


Figure 4
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. TSP1 increases U937 human monocytic cell–mediated tumoricidal activity. A, left, and B, MDA-MB-231, MDA-MB-435, and MCF-7 target cells (2 x 104/150 µL RPMI 1640 with 10% FBS) were seeded into 16-well sensor plates and incubated for up to 24 h. After this incubation, differentiated U937 effector cells (8 x 105/50 µL RPMI 1640 with 10% FBS) were directly added into wells containing target cells in the presence or absence of soluble TSP1. The measurements were automatically collected by the analyzer RT-CES system for up to 48 h. Data are representative of three different experiments. A, right, MDA-MB-231 cells (2 x 104/200 µL RPMI 1640 with 10% FBS) were seeded into 96-well plates and incubated for up to 72 h in the presence or absence of soluble TSP1 (5–20 µg/mL). At the indicated times, medium samples were collected and LDH released was measured as described in Materials and Methods. The absorbance was recorded at 490 nm. Data are representative of two different experiments. C, MDA-MB-231 target cells (2 x 104/150 µL RPMI 1640 with 10% FBS) were seeded into 16-well sensor plates and incubated for up to 24 h. After this incubation, activated ANA-1 effector cells (8 x 105/50 µL RPMI 1640 with 10% FBS and 0.5 mmol/L aminoguanidine) were directly added into wells containing target cells in the presence or absence of soluble TSP1. The measurements were automatically collected by the RT-CES system for up to 18 h. Data are representative of four different experiments. D, MDA-MB-231 target cells (2,500/100 µL RPMI 1640 with 1.25% FBS) were seeded into 96-well plates and incubated for 72 h in the presence or absence of different doses of xanthine (X) and xanthine oxidase (XO). The medium samples were collected, and LDH released was measured. The absorbance was recorded at 490 nm. The percentage of cytotoxicity is shown above each column and is calculated as (experimental – spontaneous/maximum – spontaneous) x 100. Maximum LDH release was determined by complete lysis of target cells.

 
TSP1 has been shown to enhance chemoattractant fMLP-mediated superoxide generation in human neutrophils (14), suggesting that increased ROS mediates the tumoricidal activity of TSP1-stimulated cells. To confirm sensitivity to O2–, MDA-MB-231 cells were treated with xanthine and xanthine oxidase to generate O2–. Addition of O2– dose dependently increased LDH release from the cells (Fig. 4D).

TSP1 increases extracellular release of O2–. To determine whether the known activity of TSP1 to enhance O2– release in human neutrophils extends to M1-differentiated U937 cells, IFN-{gamma}–differentiated U937 cells were stimulated with PMA (100 ng/mL), and O2– generation was assessed using luminol chemiluminescence. Incubation of differentiated U937 cells with soluble TSP1 (20 µg/mL) significantly increased (P ≤ 0.001) PMA-mediated O2– production (Fig. 5A, left ), and 25 units of SOD completely abolished this signal (data not shown), confirming that O2– was responsible for the chemiluminescent signal. This also indicates that TSP1 stimulates extracellular O2– production because SOD does not degrade intracellular O2–. Similar enhancement of O2– generation by TSP1 was observed in monocytes isolated from human PBMCs and in a murine macrophage cell line ANA-1 (Fig. 5A, middle and right). Trimeric recombinant constructs (residues 1–356) containing the N-modules of TSP1 (NoC1) and TSP2 (residues 1–359, NoC2) but not other recombinant regions of TSP1 enhanced O2– production (Fig. 5B).


Figure 5
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. TSP1 enhances extracellular release of O2– in human and mouse monocytic cells. A, left, differentiated U937 cells (5 x 105 per condition) were stimulated with PMA (100 ng/mL) in the presence or absence of soluble TSP1 (20 µg/mL) for up to 70 min, and quantitative analysis of O2– levels was performed with a LumiMax Superoxide Anion Detection kit and quantified using a luminometer. The results are presented as the ratio maximum activity [relative luminescence units (RLU)] per minute. Columns, mean of five different experiments; bars, SD. Middle, analysis of O2– release from human monocytic cells. Monocytes obtained from human PBMCs (5 x 105 per condition) were stimulated with PMA (10 ng/mL) in the presence or absence of soluble TSP1 (20 µg/mL) for 30 min. The results are presented as the ratio maximum activity (RLU) per minute. Data are representative of four different experiments. Right, activated ANA-1 cells (8 x 105 per condition) were stimulated with PMA (100 ng/mL) and aminoguanidine (0.5 mmol/L) in the presence or absence of soluble TSP1 (5 µg/mL) for 130 min. The results are presented as RLU and are representative of two different experiments. B, analysis of O2– release from differentiated U937 cells (5 x 105 per condition) stimulated as described above in the presence or absence of soluble TSP1 (20 µg/mL), NoC1, 3TSR, or E3CaG1 (10 µg/mL) for up to 40 min. The results are presented as a percentage of control RLU determined in the presence of TSP1. Columns, mean of up to four different experiments; bars, SD. C, surface {alpha}6 integrin expression in differentiated U937 cells was analyzed using flow cytometry as described in Materials and Methods. D, analysis of O2– release from differentiated U937 cells (5 x 105 per condition) stimulated as described above with soluble TSP1 (20 µg/mL) in the presence or absence of the {alpha}4β1 integrin antagonist phLDVP (1 µmol/L), the function-blocking rat anti-human {alpha}6 monoclonal antibody (clone G0H3; 5 µg/mL), p766, or control peptide (p767, 200 µmol/L) for up to 40 min. The results are presented as a percentage of control RLU determined in the presence of TSP1 alone. Columns, mean of up to five different experiments; bars, SD.

 
The N-module of TSP1 interacts with several receptors, including {alpha}3β1, {alpha}4β1, and {alpha}6β1 integrins (40). Because {alpha}3β1 integrin recognizes the N-module of TSP1 but not TSP2 (41), we examined the role of {alpha}4β1 and {alpha}6β1 integrins. Differentiated U937 cells are known to express {alpha}4β1 (42), and we found that they also express {alpha}6β1 (Fig. 5C). The {alpha}6β1-binding peptide LALERKDHSG (24) and a function-blocking {alpha}6β1 antibody partially inhibited the activity of TSP1 on O2– generation. In contrast, the {alpha}4β1 antagonist phLDVP had no effect. These results identify a specific requirement for {alpha}6β1 integrin to mediate TSP1 binding to human monocytes and the subsequent activation of intracellular signaling pathways required for O2– production (Fig. 5D).

TSP1-stimulated O2– production in macrophages requires intracellular Ca2+. Ligation of some integrins triggers a transient elevation in intracellular free Ca2+ (43, 44). Ca2+ is a second messenger for activation of NADPH oxidase in human monocytes (45). This result suggested that increased levels of Ca2+ might account for the enhancement by TSP1 of O2– production in differentiated U937 cells. Cells were loaded with Fluo-4 for 30 min and then treated with soluble TSP1 (20 µg/mL) for 25 to 50 min. Addition of TSP1 caused a significant rise in intracellular free Ca2+ (Fig. 6A ). This increase was eliminated completely following chelation of extracellular Ca2+ by the addition of 1 mmol/L EGTA (data not shown). To further confirm the role of Ca2+ in respiratory burst activity, differentiated U937 cells were treated with EGTA before the addition of PMA and TSP1. As shown in Fig. 6B, chelation of extracellular Ca2+ significantly decreased the stimulatory effect of TSP1 on PMA-mediated O2– generation in differentiated U937 cells, suggesting that a Ca2+-dependent mechanism is involved in TSP1 modulation of the macrophage respiratory burst.


Figure 6
View larger version (7K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Ca2+ is an intracellular second messenger for activation of the oxidative burst in TSP1-stimulated U937 monocytic cells. A, analysis of intracellular free Ca2+ was performed in differentiated U937 cells. U937 cells (4 x 105 per condition) were loaded with Fluo-4 for 30 min and then treated with soluble TSP1 (20 µg/mL) as described in Materials and Methods. The cells were then placed in a fluorometer and measurements were acquired for 40 min. Results are presented as fold induction in TSP1-treated (+) relative to untreated cells (–). Columns, mean of four different experiments; bars, SD. B, analysis of O2– release from differentiated U937 cells (5 x 105 per condition) stimulated with PMA (100 ng/mL) and soluble TSP1 (20 µg/mL) in the presence or absence of EGTA (1 mmol/L) for up to 45 min. The levels of O2– were determined by luminescence as described in Fig. 5. The results are presented as a percentage of control RLU determined in the presence of TSP1 alone and are representative of two different experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosure of Potential...
 References
 
Several studies have suggested that TSP1 plays an important role in the recruitment of monocytes and macrophages to sites of tissue injury or inflammation (1, 12). Here, we provide evidence that overexpression of TSP1 in tumors increases macrophage recruitment in vivo. Tumor cells produce a range of chemotactic factors for macrophages. MCP-1 stimulates recruitment of macrophages into tumors in vivo (46), and decreased expression of these chemokines was reported to limit infiltration of macrophages into an excisional wound in TSP1-null mice (1). However, soluble TSP1 did not increase MCP-1 release from differentiated U937 human monocytic cells. PAI-1 is also required for cell migration in vitro (33), and evidence is emerging for a critical role of PAI-1 in macrophage migration in vitro and in vivo (32). TSP1 up-regulates PAI-1 in pancreatic cancer cells (47), and PAI-1 expression is up-regulated in TSP1-expressing MDA-MB-435 cells (34). We found that TSP1 acutely increased PAI-1 production by differentiated human and mouse macrophages, and strong TAM expression of PAI-1 was observed in TSP1-overexpressing tumors in vivo. This acute change in PAI-1 expression in response to TSP1 is at least partially TGFβ mediated. Activation of latent TGFβ is mediated by the type 1 repeats of TSP1, but we found no induction of PAI-1 by this domain. Therefore, TSP1 probably induces PAI-1 via bound active TGFβ rather than activation of latent TGFβ produced by U937 cells. Although additional cytokines may be involved, autocrine induction of PAI-1 via tumor cell produced TSP1 as well as paracrine induction of PAI-1 expression in TAMs could increase macrophage recruitment into the tumor.

Whether increased macrophage recruitment inhibits or enhances tumor growth depends on their differentiation state. The tumor environment can educate TAMs toward a tumor-promoting phenotype (M2; ref. 18), which may prevent further macrophage migration within the tumor and ensure constant production of growth and angiogenic factors. In addition to contributing to macrophage infiltration by stimulating PAI-1 signaling in TAMs, we found that TSP1 expression in the tumor selectively increases M1 macrophage infiltration. This may provide a selective pressure distinct from its antiangiogenic activity to account for the frequently observed down-regulation of TSP1 during tumor progression and its ability to inhibit tumor growth when reexpressed.

In general, M1 macrophages are efficient producers of reactive oxygen and nitrogen intermediates that mediate resistance against tumors (17). Here, we provide evidence that tumor expression of TSP1 increases M1 polarization of TAMs assessed by iNOS expression. TSP1 was previously shown to enhance cytokine-induced and chemoattractant fMLP-induced respiratory burst in human neutrophils (13, 14). We now show that TSP1 enhances PMA-mediated respiratory burst in U937 cells differentiated along an M1 pathway using IFN-{gamma}. TSP1 stimulates the cytotoxic activity of differentiated human U937 cells and murine ANA-1 cells against several human breast carcinoma and melanoma cell lines. This contrasts with the reported activity of U937 cells to support tumor growth in an M2 manner when coinjected with prostate carcinoma cells (48). We found no effect of TSP1 on M2 differentiation of these cells in vitro. Therefore, U937 monocytes have the capacity to differentiate along both pathways, but TSP1 selectively enhances the cytotoxic effector function of M1 macrophages.

The NH2-terminal domains of TSP1 and TSP2 are sufficient for this priming activity but not for PAI-1 induction. The NH2-terminal domain of TSP1 mediates interactions with several integrin and nonintegrin receptors (40). Differentiated U937 cells express {alpha}4β1 (42) and {alpha}6β1 integrins, and inhibition of {alpha}6β1 using a TSP1 peptide or a function-blocking {alpha}6β1 antibody provides evidence that this integrin mediates intracellular signaling pathways leading to increased O2– production.

Interactions between integrins and their ligands can trigger transient elevation in intracellular free Ca2+ (43, 44), and Ca2+ is a well-known intracellular second messenger for signaling the generation of O2– in human monocytes (45). We found that addition of TSP1 to differentiated U937 cells caused a significant increase in intracellular free Ca2+ and that chelation of extracellular Ca2+ inhibits the stimulatory effect of TSP1 on mobilization of intracellular Ca2+ and PMA-mediated O2– generation in differentiated U937 cells. Taken together, these data suggest that a Ca2+-dependent mechanism is involved in TSP1 modulation of the macrophage respiratory burst. However, we cannot exclude the possibility that additional receptors recognized by the N-domains of TSP1 might contribute to O2– production by macrophages. It is interesting that the NH2-terminal region of TSP2 shares this activity to stimulate O2– production by macrophages. Loss of TSP2 has also been noted with progression in some cancers, and overexpression of TSP2 limits tumor growth in murine models (19). Our data suggest that this may involve both suppression of angiogenesis and enhancement of innate antitumor immunity.

Soluble TSP1 at 5 µg/mL was sufficient to increase U937-mediated cytotoxicity in all tumor cell targets tested. TSP1 was also reported to directly induce death of MDA-MB-231 and MCF-7 cells when used at 10 µg/mL for 24 h (49). Our results using a cytotoxicity assay based on LDH release showed minimal cytotoxic activity of soluble TSP1 against MDA-MB-231 cells even after 72 h of incubation. Our data indicate that TSP1 stimulates macrophage-mediated tumor cell death due to accumulation of ROS. Physiologic doses of O2– generated using xanthine/xanthine oxidase were sufficient to inhibit MDA-MB-231 breast carcinoma cell viability.

In conclusion, the data presented here show that stimulation of M1-differentiated human monocytic cells with TSP1 enhances tumor cell killing in vitro via production of reactive oxygen intermediates. In vivo, TSP1 promotes M1 macrophage recruitment into tumors while decreasing tumor growth. Clearly, TSP1 can also inhibit tumor growth via its antiangiogenic activity, but our results suggest that TSP1 plays an additional role in tumor immunity by increasing M1 macrophage recruitment and cytotoxicity. Avoiding this innate immune surveillance could provide a second selective pressure to reduce TSP1 expression during tumor progression.


   Disclosure of Potential Conflicts of Interest
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
References
 
No potential conflicts of interest were disclosed.


   Acknowledgments
 
Grant support: Intramural Research Program of the NIH, NCI, Center for Cancer Research (M. Tsokos, D.A. Wink, and D.D. Roberts). G. Martin-Manso is a recipient of a grant BEFI from Instituto de Salud Carlos III (Spanish Ministry of Heath).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. Deane F. Mosher and Jack Lawler for providing reagents, Dr. Douglas D. Thomas for providing reagents and help with the ROS assay, and Russell W. Bandle for help with the intracellular calcium measurements.

Received 2/20/08. Revised 6/10/08. Accepted 7/ 2/08.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
 References
 

  1. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 2002;161:831–9.[Abstract/Free Full Text]
  2. Stenina OI, Byzova TV, Adams JC, McCarthy JJ, Topol EJ, Plow EF. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004;36:1013–30.[CrossRef][Medline]
  3. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998;93:1159–70.[CrossRef][Medline]
  4. Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007;100:712–20.[Abstract/Free Full Text]
  5. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996;10:1183–91.[Abstract]
  6. Ren Y, Savill J. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J Immunol 1995;154:2366–74.[Abstract]
  7. Moodley Y, Rigby P, Bundell C, et al. Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36. Am J Pathol 2003;162:771–9.[Abstract/Free Full Text]
  8. Janabi M, Yamashita S, Hirano K, et al. Oxidized LDL-induced NF-{kappa}B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000;20:1953–60.[Abstract/Free Full Text]
  9. Yamauchi Y, Kuroki M, Imakiire T, et al. Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937. Biochem Biophys Res Commun 2002;290:1551–7.[CrossRef][Medline]
  10. Suchard SJ. Interaction of human neutrophils and HL-60 cells with the extracellular matrix. Blood Cells 1993;19:197–221.[Medline]
  11. Mansfield PJ, Boxer LA, Suchard SJ. Thrombospondin stimulates motility of human neutrophils. J Cell Biol 1990;111:3077–86.[Abstract/Free Full Text]
  12. Mansfield PJ, Suchard SJ. Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes. J Immunol 1994;153:4219–29.[Abstract]
  13. Nathan C, Srimal S, Farber C, et al. Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol 1989;109:1341–9.[Abstract/Free Full Text]
  14. Suchard SJ, Boxer LA, Dixit VM. Activation of human neutrophils increases thrombospondin receptor expression. J Immunol 1991;147:651–9.[Abstract]
  15. Majluf-Cruz A, Manns JM, Uknis AB, et al. Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays. J Lab Clin Med 2000;136:292–302.[CrossRef][Medline]
  16. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605–12.[Abstract/Free Full Text]
  17. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007;37:14–6.[CrossRef][Medline]
  18. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–8.[CrossRef][Medline]
  19. Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 2008;65:672–86.[CrossRef][Medline]
  20. Roberts DD, Cashel J, Guo N. Purification of thrombospondin from human platelets. J Tissue Cult Methods 1994;16:217–22.[CrossRef]
  21. Misenheimer TM, Huwiler KG, Annis DS, Mosher DF. Physical characterization of the procollagen module of human thrombospondin 1 expressed in insect cells. J Biol Chem 2000;275:40938–45.[Abstract/Free Full Text]
  22. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and -independent mechanisms. Cancer Res 2001;61:7830–9.[Abstract/Free Full Text]
  23. Anilkumar N, Annis DS, Mosher DF, Adams JC. Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. J Cell Sci 2002;115:2357–66.[Abstract/Free Full Text]
  24. Calzada MJ, Sipes JM, Krutzsch HC, et al. Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by {alpha}6β1 integrin. J Biol Chem 2003;278:40679–87.[Abstract/Free Full Text]
  25. Lin K, Ateeq HS, Hsiung SH, et al. Selective, tight-binding inhibitors of integrin {alpha}4β1 that inhibit allergic airway responses. J Med Chem 1999;42:920–34.[CrossRef][Medline]
  26. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504–11.[Abstract/Free Full Text]
  27. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17:565–77.[Medline]
  28. Cox GW, Mathieson BJ, Gandino L, Blasi E, Radzioch D, Varesio L. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J Natl Cancer Inst 1989;81:1492–6.[Abstract/Free Full Text]
  29. Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 1997;50:210–21.[Medline]
  30. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007;104:13–9.[CrossRef][Medline]
  31. Lu B, Rutledge BJ, Gu L, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998;187:601–8.[Abstract/Free Full Text]
  32. Cao C, Lawrence DA, Li Y, et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006;25:1860–70.[CrossRef][Medline]
  33. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004;279:22595–604.[Abstract/Free Full Text]
  34. Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000;83:298–306.[CrossRef][Medline]
  35. Song CZ, Siok TE, Gelehrter TD. Smad4/DPC4 and Smad3 mediate transforming growth factor-β (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 1998;273:29287–90.[Abstract/Free Full Text]
  36. Murphy-Ullrich JE, Schultz-Cherry S, Hook M. Transforming growth factor-β complexes with thrombospondin. Mol Biol Cell 1992;3:181–8.[Abstract]
  37. Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-β complex. J Biol Chem 2004;279:47633–42.[Abstract/Free Full Text]
  38. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998;160:5347–54.[Abstract/Free Full Text]
  39. Thomas DD, Ridnour LA, Espey MG, et al. Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem 2006;281:25984–93.[Abstract/Free Full Text]
  40. Calzada MJ, Roberts DD. Novel integrin antagonists derived from thrombospondins. Curr Pharm Des 2005;11:849–66.[CrossRef][Medline]
  41. Calzada MJ, Zhou L, Sipes JM, et al. {alpha}4β1 Integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res 2004;94:462–70.[Abstract/Free Full Text]
  42. Prieto J, Eklund A, Patarroyo M. Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell Immunol 1994;156:191–211.[CrossRef][Medline]
  43. Jaconi ME, Theler JM, Schlegel W, Appel RD, Wright SD, Lew PD. Multiple elevations of cytosolic-free Ca2+ in human neutrophils: initiation by adherence receptors of the integrin family. J Cell Biol 1991;112:1249–57.[Abstract/Free Full Text]
  44. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R, Dedhar S. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997;386:843–7.[CrossRef][Medline]
  45. Scully SP, Segel GB, Lichtman MA. Relationship of superoxide production to cytoplasmic free calcium in human monocytes. J Clin Invest 1986;77:1349–56.[CrossRef][Medline]
  46. Hoshino Y, Hatake K, Kasahara T, et al. Monocyte chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages into tumors in tumor-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow. Exp Hematol 1995;23:1035–9.[Medline]
  47. Albo D, Berger DH, Vogel J, Tuszynski GP. Thrombospondin-1 and transforming growth factor β-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J Gastrointest Surg 1999;3:411–7.[CrossRef][Medline]
  48. Craig M, Ying C, Loberg RD. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J Cell Biochem 2008;103:1–8.[CrossRef][Medline]
  49. Manna PP, Frazier WA. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 2004;64:1026–36.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Sci Transl MedHome page
J. B. Maxhimer, D. R. Soto-Pantoja, L. A. Ridnour, H. B. Shih, W. G. DeGraff, M. Tsokos, D. A. Wink, J. S. Isenberg, and D. D. Roberts
Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling
Science Translational Medicine, October 21, 2009; 1(3): 3ra7 - 3ra7.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S.-Y. Kang, O. J. Halvorsen, K. Gravdal, N. Bhattacharya, J. M. Lee, N. W. Liu, B. T. Johnston, A. B. Johnston, S. A. Haukaas, K. Aamodt, et al.
Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1
PNAS, July 21, 2009; 106(29): 12115 - 12120.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin-Manso, G.
Right arrow Articles by Roberts, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin-Manso, G.
Right arrow Articles by Roberts, D. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online